PGC heads into its July 27 earnings date with analyst conviction rising, short interest creeping higher, and insiders sending a notably mixed message.
The Street has grown steadily more bullish on Peapack-Gladstone Financial over recent weeks. Raymond James lifted its target to $55 this week — from $49 — while maintaining a Strong Buy. Piper Sandler moved to $54 from $50 last Thursday, keeping its Overweight rating. Both moves arrive with the stock trading near $47.33, implying roughly 15-17% upside to those fresh targets. The consensus mean sits at $49.44, which has lagged the recent round of upgrades and will likely drift higher as the Street catches up. The direction of travel here is unambiguous: analysts have been raising targets consistently since late 2025, with no cuts in the recent window.
Beneath the bullish analyst tone, short positioning has been quietly building. Short interest has climbed to 3.5% of the free float — up 15.7% over the past month and roughly 7% on the week alone. That is not an extreme level by any measure, but the trajectory is worth noting heading into a catalyst. Cost to borrow has risen 44% on the week, though it remains very cheap in absolute terms at 0.57%. The lending market itself is nowhere near stressed: availability is extremely loose at 1,728%, meaning more than 17 shares are available to borrow for every one already out on loan. This is a far cry from a squeeze setup — positioning looks more like cautious hedging than a crowded short.
Options sentiment tells a broadly constructive story. The put/call ratio is running at 0.11, fractionally above its 20-day average of 0.10 and less than one standard deviation above that mean. Options flow skews heavily toward calls, consistent with a market that sees more upside potential than downside risk into the upcoming print. The ORTEX short score is benign at 40.4, ranking in just the 22nd percentile for short pressure within its universe — this is not a stock that bears are aggressively pressing.
The insider picture introduces a wrinkle. Looking back to late March, the CEO, CFO, and a director clustered into the stock at around $35, spending nearly $550,000 collectively. That was a clear vote of confidence at lower prices. More recently, three different executives have been selling — an EVP, a divisional president, and the chief accounting officer disposed of shares in June and on June 29, booking gains as the stock ran from the mid-$30s. None of the sales are large in absolute dollar terms, and the 90-day net position is still a modest positive at roughly 13,500 shares net bought. But the shift from cluster buying to incremental selling as the stock approaches analyst targets is a pattern worth tracking. On the fundamental side, the bull case rests on NII growth running at nearly 38% year-on-year and accelerating loan growth across residential, multifamily, and C&I. The bear case focuses on elevated expenses tied to the NYC metro expansion and near-term asset quality headwinds — a combination that contributed to the stock's sharp post-earnings drop earlier this year.
Close peers moved broadly in line this week. WTBA gained 3.5% and SRCE added 3.3%, bracketing PGC's own 3.3% weekly advance — suggesting sector tailwinds rather than stock-specific outperformance drove the move.
The July 27 earnings print is the event that matters most now: the question is whether NII momentum and loan growth are enough to offset the persistent expense pressure that has tripped the stock before.
See the live data behind this article on ORTEX.
Open PGC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
